Simple Summary
Diffusion-weighted magnetic resonance imaging (DW-MRI) is a widely used noninvasive technique for the characterization of tumor cellularity in head and neck cancers (HNC). The new vendor-provided Low Variance (LOVA) apparent diffusion coefficient (ADC) gradient nonlinearity correction (GNC) technique improves the accuracy of the ADC values. This GNC method was initially tested for breast cancer patients. The present study aimed to investigate the performance of the LOVA GNC method for HNC patient ADC. The GNC-corrected mean ADC values of primary tumors and metastatic neck nodes were lower than the uncorrected ADC values. The shift in ADC histograms for primary tumor and metastatic nodes was observed with and without the application of GNC. The results showed that implementing GNC improves the ADC measurements.
Abstract
Background/Objectives: This work prospectively evaluates the vendor-provided Low Variance (LOVA) apparent diffusion coefficient (ADC) gradient nonlinearity correction (GNC) technique for primary tumors, neck nodal metastases, and normal masseter muscles in patients with head and neck cancers (HNCs). Methods: Multiple b-value diffusion-weighted (DW)-MR images were acquired on a 3.0 T scanner using a single-shot echo planar imaging (SS-EPI) and multi-shot (MS)-EPI for diffusion phantom materials (20% and 40% polyvinylpyrrolidone (PVP) in water). Pretreatment DW-MRI acquisitions were performed for sixty HNC patients (n = 60) who underwent chemoradiation therapy. ADC values with and without GNC were calculated offline using a monoexponential diffusion model over all b-values, relative percentage (r%) changes (Δ) in ADC values with and without GNC were calculated, and the ADC histograms were analyzed. Results: Mean ADC values calculated using SS-EPI DW data with and without GNC differed by ≤1% for both PVP20% and PVP40% at the isocenter, whereas off-center differences were ≤19.6% for both concentrations. A similar trend was observed for these materials with MS-EPI. In patients, the mean rΔADC (%) values measured with SS-EPI differed by 4.77%, 3.98%, and 5.68% for primary tumors, metastatic nodes, and masseter muscle. MS-EPI exhibited a similar result with 5.56%, 3.95%, and 4.85%, respectively. Conclusions: This study showed that the GNC method improves the robustness of the ADC measurement, enhancing its value as a quantitative imaging biomarker used in HNC clinical trials.